Targeting RAS-mutant cancer cells using a synthetic RAS-activated cancer killing system

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Oncogenic RAS proteins are frequently mutated in cancer but remain difficult pharmacological targets.
• Current cancer therapies often struggle with acquired resistance and targeting specific mutations effectively.

Purpose of the Study:

• To develop a novel synthetic platform for targeted identification and elimination of RAS-mutant cancer cells.
• To create a system that overcomes resistance mechanisms and targets a broad range of oncogenic mutations.

Main Methods:

• Development of a RAS-activated cancer killing (RACK) system utilizing a highly specific transcriptional sensor for oncogenic RAS signals.
• Testing RACK's efficacy against various RAS and non-RAS mutants (KRAS, NRAS, BRAF, RTKs) in vitro.
• Evaluating RACK's performance in vivo using xenograft models, including those resistant to conventional inhibitors.

Main Results:

• RACK demonstrated potent and specific targeting of RAS-mutant cancer cells.
• The system maintained efficacy against cancer cells with acquired resistance, outperforming existing inhibitors.
• In vivo studies showed selective inhibition of RAS-mutant tumor growth, including in models resistant to allele-specific inhibitors.

Conclusions:

• The RACK system represents a pioneering drug approach for detecting and treating RAS-mutant cancers.
• RACK's modular design allows for optimization and broad applicability.
• This platform offers a promising strategy to address challenges posed by currently undruggable cancer targets.